FUNDAMENTALS · Fundamentals · HK Healthcare

Grand Pharmaceutical Group (0512) Fundamentals 2026 — P/E 15.2x, Revenue Analysis | SniperIQ

Grand Pharmaceutical Group (0512) is a HK-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of HK

8.6B, trading at HK$5.32 on the HKSE. This SniperIQ fundamentals page covers Grand Pharmaceutical Group's valuation (P/E 15.2x, P/B 1.1x), profitability (net margin 10.1%), revenue (HK
2.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
8.6B
P/E (TTM)15.2x
Net Margin10.1%
Revenue (FY25)HK
2.3B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Grand Pharmaceutical Group's market cap?

Grand Pharmaceutical Group (0512) has a market capitalization of approximately HK

8.6B, trading at HK$5.32 on the HKSE. Market cap moves with the live share price.

What is Grand Pharmaceutical Group's P/E ratio?

Grand Pharmaceutical Group's trailing twelve-month P/E ratio is 15.2x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Grand Pharmaceutical Group?

Grand Pharmaceutical Group runs a net profit margin of 10.1%, a gross margin of 55.2%, and an operating margin of 8.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Grand Pharmaceutical Group generate?

Grand Pharmaceutical Group reported revenue of HK

2.3B for fiscal year 2025, with net income of HK
.2B and earnings per share (EPS) of 0.35. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Grand Pharmaceutical Group pay a dividend?

Grand Pharmaceutical Group offers a trailing dividend yield of about 3.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Grand Pharmaceutical Group financially healthy?

Grand Pharmaceutical Group carries a debt-to-equity ratio of 0.28x and a current ratio of 1.14x, with a market beta of 0.66. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Grand Pharmaceutical Group a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Grand Pharmaceutical Group (0512) the key facts are: market cap HK

8.6B, P/E 15.2x, revenue HK
2.3B, 52-week range 4.53-9.88. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Grand Pharmaceutical Group's full fundamentals live

Get Grand Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Kangmei Pharmaceutical (600518) fundamentals · StemRIM (4599) fundamentals · Autobio Diagnostics (603658) fundamentals · Windlas Biotech (WINDLAS) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons